SARS-CoV-2 InfectionsQUANTICO-PRONCT05278390
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic
A study testing Thoracic CT scan in people with SARS-CoV-2 Infections and Respiratory Failure With Hypoxia, run by University Hospital, Strasbourg, France at 2 sites in France.
Trial summary
Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- SARS-CoV-2 Infections, Respiratory Failure With Hypoxia
- What is being tested?
- Thoracic CT scan
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 2 sitesFrance
- Study dates
- 13 Jun 2022to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject admitted to a care unit of the University Hospitals of Strasbourg or the University Hospital of Nancy and presenting a suspicion of SARS-CoV-2 infection or postoperative hypoxemic respiratory failure
- Able to understand the objectives and risks of the research and to give dated and signed informed consent.
- Subjects may also be included in emergency or immediate life-threatening situations.
- Subject with insurance covering
Who cannot join
- Pregnant woman (pregnancy confirmed by a urine or blood test)
- Subject usually on home oxygen therapy
- Subject under court protection
- Subject under guardianship or curatorship
Trial locations and contacts
2 sites in 1 country.
France2 sites
Service d'anesthésie réanimation-CHU de Nancy
Nancy, 54500
Service d'Anesthésie-Réanimation - CHU Strasbourg
Strasbourg, 67098
About this study
Official title: Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic : Prospective Multicenter Cohort Study
Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example.
This study aims at assessing the correlation between the amount of radiologic pulmonary alteration and the clinical severity in two clinical situation :
- SARS-CoV-2 infections
- Postoperative hypoxemic acute respiratory failure.
- Being tested
- Thoracic CT scan
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thoracic CT scanRadiation
Automated quantitative analysis of altered pulmonary volume
| Study group | Role | What they receive |
|---|---|---|
| Thoracic CT Scan | Experimental | Not described Receives: Radiation: Thoracic CT scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between altered pulmonary volume and ordinal severity scale
This criterion will be expressed as a score between 1 (least severe) and 7 (most severe).
Measured: 2 days after CT scan (Day 2)
Secondary outcomes (4)
Correlation between altered pulmonary volume and ordinal severity scale
This criterion will be expressed as a score between 1 (least severe) and 7 (most severe).
Measured: 7 days after CT scan (Day 7)
Mortality
Measured: 90 days following CT scan (Day 90)
Rate of admission to intensive care unit
Measured: 28 days following CT scan (Day 28)
Initial length of hospitalization stay (in days)
Measured: 90 days following CT scan (Day 90)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2022
- Study start13 Jun 2022
- Primary completion8 Apr 2025
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SARS-CoV-2 InfectionsStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Collaborators
- REGION GRAND EST, E-MEDIA, VISIBLE PATIENT
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05278390
- Sponsor's protocol ID
- 8138
- Acronym
- QUANTICO-PRO
- Status last verified
- Jun 2026
- First submitted
- 11 Mar 2022
- Last updated
- 8 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic : Prospective Multicenter Cohort Study
- ClinicalTrials.gov ID
- NCT05278390
- Acronym / sponsor ID
- QUANTICO-PRO / 8138
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Collaborators
- REGION GRAND EST, E-MEDIA, VISIBLE PATIENT
- Study start
- 13 Jun 2022 (actual)
- Primary completion
- 8 Apr 2025 (actual)
- Study completion
- Jun 2027 (estimated)
- First posted
- 14 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example.
This study aims at assessing the correlation between the amount of radiologic pulmonary alteration and the clinical severity in two clinical situation :
- SARS-CoV-2 infections
- Postoperative hypoxemic acute respiratory failure.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Thoracic CT Scan | Experimental | Radiation: Thoracic CT scan |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Subject admitted to a care unit of the University Hospitals of Strasbourg or the University Hospital of Nancy and presenting a suspicion of SARS-CoV-2 infection or postoperative hypoxemic respiratory failure
- Able to understand the objectives and risks of the research and to give dated and signed informed consent.
- Subjects may also be included in emergency or immediate life-threatening situations.
- Subject with insurance covering
Key exclusion criteria (4 listed)
- Pregnant woman (pregnancy confirmed by a urine or blood test)
- Subject usually on home oxygen therapy
- Subject under court protection
- Subject under guardianship or curatorship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thoracic CT scanAutomated quantitative analysis of altered pulmonary volume | Radiation | Thoracic CT Scan |
Primary outcome
Correlation between altered pulmonary volume and ordinal severity scale
Time frame: 2 days after CT scan (Day 2)
This criterion will be expressed as a score between 1 (least severe) and 7 (most severe).
4 secondary outcomes
Correlation between altered pulmonary volume and ordinal severity scale
Time frame: 7 days after CT scan (Day 7)
Mortality
Time frame: 90 days following CT scan (Day 90)
Rate of admission to intensive care unit
Time frame: 28 days following CT scan (Day 28)
Initial length of hospitalization stay (in days)
Time frame: 90 days following CT scan (Day 90)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for SARS-CoV-2 Infections
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thoracic CT scan in people with SARS-CoV-2 Infections and Respiratory Failure With Hypoxia, run by University Hospital, Strasbourg, France at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between altered pulmonary volume and ordinal severity scale (time frame: 2 days after CT scan (Day 2)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.